ArticleBMJ oncology2023
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study.
Article in BMJ oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020-2024).Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026Pooled it
- Blinding and quality of life endpoints in randomised trials of stable angina: a meta-epidemiological study.Open heart · 2026Pooled it
- Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.The oncologist · 2025Pooled it
- Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review.BMJ open · 2024Pooled it
- Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.Breast cancer (Tokyo, Japan) · 2024Pooled it
- International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Quality of life in oncology drug approvals: evidence from Swiss decisions in relation to global regulatory trends.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Patient Experiences Regarding Feasibility of Implementing Real-World EQ-5D Collection at an Oncology Centre in Ontario, Canada.Current oncology (Toronto, Ont.) · 2025Article
- Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review.Pharmaceutical medicine · 2025Review
- Article
- Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report.Drugs in context · 2025Article
- Health-related quality of life assessment in head and neck cancer: A systematic review of phase II and III clinical trials.Heliyon · 2024Article
- Article
- Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005-2020: an observational study.The Lancet regional health. Western Pacific · 2024Article
- Review
- Availability of quality-of-life results for clinical decisions: an evolving scenario.BMJ oncology · 2024Article
- Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology.BMJ oncology · 2024Article
- Careful take-off by the EQ-5D-5L tool in lung cancer: fly little one, fly!BMJ oncology · 2024Article
- Modern cancer trials still lack information about QoL impacts on patients.BMJ oncology · 2023Article
- Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials.JCO oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess time trends in the inclusion of health-related quality of life (QoL) among study endpoints and in the reporting of QoL results in study publications, randomised phase III oncology trials published between 2017 and 2021 were compared with the trials published in the previous 5 years. Methods and analysis: All issues published between 2012 and 2021 by 11 major journals were handsearched for primary publications of phase III trials in adult patients with solid tumours. Trials published in 2017-2021 were compared with trials published in 2012-2016 for three endpoints: (1) proportion of publications including QoL among endpoints out of all the eligible publications; (2) proportion of publications presenting QoL results out of those including QoL among endpoints and (3) proportion of publications presenting QoL data out of all the eligible publications. Results: 388 publications between 2017 and 2021 were eligible and compared with 446 publications between 2012 and 2016. QoL was included among endpoints in 67.8% of trials in 2017-2021 vs 52.9% in 2012-2016 (univariate OR 1.87, 95% CI 1.41 to 2.48, p<0.001). QoL results were available in 52.1% in 2017-2021 vs 62.3% in 2012-2016 of primary publications of trials including QoL among endpoints (OR 0.66, 95% CI 0.46 to 0.94, p=0.02). Overall, QoL was analysed and presented in 35.3% of primary publications in 2017-2021 vs 33.0% in 2012-2016 (OR 1.11, 95% CI 0.83 to 1.48, p=0.48). Conclusions: The proportion of oncology trials including QoL among endpoints increased in 2017-2021 compared with 2012-2016. However, the proportion of primary publications reporting QoL results remains suboptimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.